Volume 18, Issue 4, Pages (June 2015)

Slides:



Advertisements
Similar presentations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.
Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.
Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,
Volume 14, Issue 8, Pages (December 2011)
Volume 15, Issue 8, Pages (December 2012)
Volume 18, Issue 5, Pages (July 2015)
Volume 18, Issue 2, Pages (March 2015)
Mapping the COPD Assessment Test onto EQ-5D
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results  Becky Pennington, MSc,
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-
Volume 17, Issue 2, Pages (March 2014)
Volume 14, Issue 1, Pages (January 2011)
Volume 18, Issue 4, Pages (June 2015)
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Volume 14, Issue 4, Pages (June 2011)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 17, Issue 8, Pages (December 2014)
Volume 14, Issue 4, Pages (June 2011)
Volume 15, Issue 2, Pages (March 2012)
Volume 15, Issue 6, Pages (September 2012)
Volume 14, Issue 8, Pages (December 2011)
Volume 15, Issue 1, Pages (January 2012)
Volume 19, Issue 5, Pages (July 2016)
Volume 15, Issue 2, Pages (March 2012)
Volume 17, Issue 2, Pages (March 2014)
Examining the Value of Menopausal Symptom Relief Among US Women
Volume 17, Issue 2, Pages (March 2014)
Volume 18, Issue 2, Pages (March 2015)
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Louis L. Nguyen, MD, MBA, MPH  Journal of Vascular Surgery 
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011  Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems  Randall Winnette, MSc, Victor Zárate, MD, MSc,
Omneya Mohamed, PhD, David H. Kreling, PhD 
Value in Health Regional Issues
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Volume 18, Issue 4, Pages 457-466 (June 2015) Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy  Chiara de Waure, MD, MSc, PhD, Stefano Capri, MSc, Maria Assunta Veneziano, MSc, PhD, Maria Lucia Specchia, MD, PhD, Chiara Cadeddu, MD, Francesco Di Nardo, MD, Anna Maria Ferriero, MD, Francesca Gennari, PhD, Colette Hamilton, MSc, MBA, Agostino Mancuso, MD, Gianluigi Quaranta, MD, MSc, Matteo Raponi, MD, Luca Valerio, MD, Gianfranco Gensini, MD, Walter Ricciardi, MD, MSc  Value in Health  Volume 18, Issue 4, Pages 457-466 (June 2015) DOI: 10.1016/j.jval.2015.01.009 Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 PSA results (scatter plots). ECP, extracorporeal photopheresis; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted lie-year. Value in Health 2015 18, 457-466DOI: (10.1016/j.jval.2015.01.009) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Results of budget impact analysis. Value in Health 2015 18, 457-466DOI: (10.1016/j.jval.2015.01.009) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.